Transarterial (Chemo-)Embolization and Lipiodolization for Hepatic Haemangioma

• Published in: Cardiovascular and interventional radiology 2019-06, Vol.42 (6), p.800-811
• Main Authors: Furumaya, Alicia, van Rosmalen, Belle V., Takkenberg, R. Bart, van Delden, Otto M., Dejong, Cornelis H. C., Verheij, Joanne, van Gulik, Thomas M.
• Format: Article
• Language: English
• Subjects: Arterial Interventions; Authorship; BIOMEDICAL RADIOGRAPHY; Cardiology; Case reports; Chemoembolization; CLINICAL TRIALS; Complications; Embolization; Hemangioma; Imaging; LIVER; Liver cancer; Medical research; Medicine; Medicine & Public Health; Mortality; NEOPLASMS; Nuclear Medicine; PATIENTS; Quality assessment; Quality control; QUALITY OF LIFE; Radiology; RADIOLOGY AND NUCLEAR MEDICINE; RECOMMENDATIONS; Review; REVIEWS; Signs and symptoms; SURGERY; SYMPTOMS; Tumors; Ultrasound; VASCULAR DISEASES
• ISSN: 0174-1551; 1432-086X
• DOI: 10.1007/s00270-019-02169-x

Background Transarterial (chemo-)embolization/lipiodolization (TAE/TAL) might be an attractive minimally invasive alternative to surgery in the treatment of symptomatic hepatic haemangioma. This review assesses the efficacy and safety of TAE/TAL as primary treatment for symptomatic hepatic haemangioma. Methods A systematic search of the literature was performed by two reviewers following the PRISMA guidelines. Cohort studies and case reports were identified; outcomes of cohort studies were reported. The primary efficacy outcome was tumour size before and after TAE/TAL. Improvement of symptoms and quality of life (QoL) were secondary outcomes; the primary safety outcome was complications. The Downs and Black statement was used for quality assessment. Results Eighteen cohort studies were identified, including 1284 patients. TAE/TAL led to a decrease in tumour size in 1100/1223 (89.9%) patients and to improvement or disappearance of symptoms in 1080/1096 (98.5%) patients. A significant decrease in tumour size from 9.79 ± 0.79 cm to 4.00 ± 1.36 cm ( p